AVB-500, a high-affinity AXL fusion protein, effectively increasing the chemosensitivity of ovarian cancer and endometrial cancer [9, 10], is currently being tested in a Phase Ib clinical trial against platinum-resistant ovarian cancer [11]. This evidence concerns the gene AXL and ovarian carcinoma.